Computational chemistry has played a central role in early-stage drug discovery by accelerating target selection, hit identification, and lead optimization. This review summarizes recent developments in molecular docking, pharmacophore modeling, molecular dynamics (MD), and virtual screening (VS), with a focus on their application in practical drug discovery workflows. Advances in docking protocols, including consensus scoring, physics-based rescoring, and ensemble approaches, addressed the challenges of receptor flexibility. Both ligand-based and structure-based pharmacophore models facilitated scaffold hopping and guided library prioritization. MD simulations were used to assess binding pose stability, identify cryptic binding pockets, and characterize solvent interactions. These simulations also supported free-energy calculations using endpoint and alchemical methods. Large-scale VS campaigns employed curated compound libraries, often composed of make-on-demand molecules, and relied on high-performance computing or cloud infrastructure to screen up to 109 compounds. Hits were validated using orthogonal biophysical assays and filtered by absorption, distribution, metabolism, excretion, and toxicity (ADMET) predictions. Integrated pipelines combining pharmacophore modeling, docking, MD, and free-energy calculations improved enrichment rates and reduced the number of compounds requiring synthesis. Several case studies demonstrated the identification of nanomolar-affinity leads from ultra-large screening campaigns. The review also addressed ongoing challenges, such as inconsistent scoring of binding affinity, protonation, and tautomeric errors, dataset bias, and reproducibility issues. Strategies to mitigate these limitations included standardized library preparation, adherence to FAIR (Findable, Accessible, Interoperable, and Reusable) data principles, and the use of prospective benchmarking protocols. The review discussed emerging trends, including the use of quantum chemistry for electronic structure refinement, ensemble docking guided by cryo-electron microscopy (cryo-EM) data, and the integration of computational tools with automated synthesis and high-throughput screening in closed-loop discovery systems. These approaches have the potential to accelerate the design–make–test cycle, increase hit novelty, and improve decision-making in early drug development programs.
Altharawi et al. (Fri,) studied this question.